¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 Á¦ 17Â÷ ´ëÇѹé½ÅÇÐȸ Ãá°èÇмú´ëȸ : 2021-03-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 Á¦ 17Â÷ ´ëÇѹé½ÅÇÐȸ Ãá°èÇмú´ëȸ : 2021-03-26
±³À°ÀÏÀÚ : 2021-03-26
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 Á¦ 17Â÷ ´ëÇѹé½ÅÇÐȸ Ãá°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ
´ã´çÀÚ : ÃÖ¼ö¿¬
¿¬¶ôó : 02-740-8364  
À̸ÞÀÏ : office@korvac.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ,      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í È¸¿ø 1) Àü¹®ÀÇ,¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ¿¬±¸ÀÚ: »çÀüµî·Ï 5¸¸¿ø/Ãß°¡µî·Ï 7¸¸¿ø 2) Àü°øÀÇ, ´ëÇлý, ´ëÇпø»ý ¹× ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø: »çÀüµî·Ï 3¸¸¿ø/Ãß°¡µî·Ï 5¸¸¿ø ºñȸ¿ø »çÀüµî·Ï 8¸¸¿ø/Ãß°¡µî·Ï 10¸¸¿ø (ÇöÀåµî·Ï ºÒ°¡)      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
È޽Ġ03¿ù 26ÀÏ ¿Â¶óÀΠ08:50~09:00 Opening  È²ÀÀ¼ö(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ09:00~09:30 COVID-19 global epidemiology – past, present and future prospects  Ben Cowling(È«Äá´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ09:30~10:00 SARS-CoV-2 mutations and clinical implication  ¹Ú¸¸¼º(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ10:00~10:30 Treatment strategy based on the pathogenesis of SARS-CoV-2  ±è¼ºÇÑ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ10:30~10:40 Q&A  () 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ10:40~11:10 Vaccine adjuvants: classification & mode of action  À̳ª°æ(¼¼Á¾´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ11:10~11:40 Viral vector delivery system  ÃÖÁ¤¾Æ(±¹Á¦¹é½Å¿¬±¸¼Ò) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ11:40~12:10 Lipid nanoparticle for mRNA vaccine platform  ¹æÀº°æ(Çѱ¹°úÇбâ¼ú¿¬±¸¿ø) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ12:10~12:20 Q&A  () 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ12:20~12:45 Rapid Development of a Highly Effective RNA-Based COVID-19 Vaccine  Philip R. Dormitzer(Pfizer) 
½Ä»ç 03¿ù 26ÀÏ ¿Â¶óÀΠ12:45~13:20 Lunch  () 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ13:20~13:50 Efficacy of COVID-19 vaccines  ±èÅÂÇü(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ13:50~14:20 Safety of COVID-19 vaccines  Á¤ÈñÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ14:20~14:50 Strategies for COVID-19 vaccination: allocation, distribution, and communication  È«Á¤ÀÍ(Áúº´°ü¸®Ã») 
Åä·Ð 03¿ù 26ÀÏ ¿Â¶óÀΠ14:50~15:05 Panel discussion  () 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ15:05~15:35 Interspecies transmission of zoonotic coronaviruses from SARS to COVID-19  ¼Û´ë¼·(°í·Á´ë ¾àÇдë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ15:35~16:05 SARS-CoV-2 infection in farmed minks - zoonotic concerns  °­ÇØÀº(³ó¸²Ãà»ê°Ë¿ªº»ºÎ) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ16:05~16:15 Q&A  () 
È޽Ġ03¿ù 26ÀÏ ¿Â¶óÀΠ16:15~16:20 Coffee break  () 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ16:20~16:50 Influenza, RSV and COVID-19: similar but different diseases  ±è¿¹Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ16:50~17:20 Impacts of the COVID-19 Pandemic on routine pediatric immunization  ÃÖ¿µÁØ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 03¿ù 26ÀÏ ¿Â¶óÀΠ17:20~17:30 Q&A  () 
È޽Ġ03¿ù 26ÀÏ  17:30~17:30 Closing  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 Á¦ 17Â÷ ´ëÇѹé½ÅÇÐȸ Ãá°èÇмú´ëȸ : 2021-03-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽŰæ°úÇÐȸ ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ Ãá°èÁý´ãȸ : 2021-03-26
´ÙÀ½±Û °Ç±¹´ëÇб³ÃæÁÖº´¿ø (¿Â¶óÀÎ) ´ç´¢º´ Àν¶¸°ÆßÇÁ ¼¼¹Ì³ª : 2021-03-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 3 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 3 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 107 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 9 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 25 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 10 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 5 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 4 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 1 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 6 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 9 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 7 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷